Discovery Of The Missing Link Between HPV Infection And Cervical Cancer Development Could Offer A New Screening And Therapeutic Strategy
4/06/2011

Most women are infected with human papillomavirus (HPV), which can cause cervical cancer - yet few develop the cancer. Now researchers at Georgetown Lombardi Comprehensive Cancer Center, a part of Georgetown University Medical Center, believe they have found the missing link explaining why: activation of the beta-catenin oncogene...

ImmunoGen, Inc. Announces First Data For Its Novel Therapeutic For Ovarian Cancer And Other Carcinomas
4/05/2011

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the reporting of the first data on the Company's IMGN853 product candidate for the treatment of ovarian cancer and other types of solid tumors...

Association Between BRCA2 Mutations And Improved Survival For Ovarian Cancer
4/05/2011

Women with ovarian cancer who have the BRCA2 gene mutation are more likely to survive the malignancy than women with the BRCA1 mutation, or women without either mutation. In results presented at the AACR 102nd Annual Meeting 2011, held April 2-6, Kelly Bolton, a fellow at the National Cancer Institute, said the findings describe the effect of these mutations in ovarian cancer survival...

Risk For Lung Cancer Increases In The Presence Of HPV Antibodies
4/05/2011

Researchers with the International Agency for Research on Cancer (IARC) have found that people with lung cancer were significantly more likely to have several high-risk forms of human papillomavirus (HPV) antibodies compared to those who did not have lung cancer...

Neogenix Oncology To Present Data On Its Novel Antibody, NEO-201 At AACR's 2011 Annual Symposium
4/04/2011

Neogenix Oncology, Inc. announced that members of its scientific staff will present laboratory studies of NEO-201, a novel monoclonal antibody in development to diagnose and treat solid tumors of the gastrointestinal tract, lung and respiratory tract, breast, and ovarian cancers...

Chronic Stress Of Cancer Causes Accelerated Telomere Shortening
4/03/2011

Results of a study presented at the AACR 102nd Annual Meeting 2011, held here April 2-6, lend credence to the idea that improving quality of life affects stress-related biological markers and possibly the health of people with cancer. Researchers know that telomeres shorten and deteriorate with aging, but they are learning that stress also affects telomere length...

Pivotal Study Validates Roche's Cobas(R) HPV Test With HPV-16 And 18 Genotyping For Identifying Women In The UK At Highest Risk For Cervical Cancer
4/01/2011

Roche announced today that a recent study published online in the American Journal of Clinical Pathology demonstrated the ability of the cobas® Human Papillomavirus (HPV) Test to individually detect HPV-16 and HPV-18, two of the highest risk HPV genotypes causing 70 percent of cervical cancer cases...

mtm's P16/Ki-67 Dual Immuno-Staining Identifies High-Grade Cervical Disease In ASC-US And LSIL With High Sensitivity And Specificity
3/30/2011

mtm laboratories, a privately held diagnostics company developing, manufacturing and globally commercializing in vitro diagnostics for cervical cancer early detection and diagnosis, today announced the publication of a new paper showing that dual staining for p16 and Ki-67 can pinpoint the underlying high-grade cervical disease with a high degree of sensitivity and specificity ...

Benitec Limited Technology Used By University Of Queensland Scientists To Develop A Treatment For Cervical Cancer
3/29/2011

Benitec Limited (ASX:BLT) (PINK:BNIKF) today welcomed the publication of research by scientists at the University of Queensland who demonstrated the value of Benitec's gene silencing platform technology to provide effective human therapeutics for cancer. Their results were published this month in the prestigious international scientific journal Cancer Gene Therapy*...

Ovarian Cancer Research Benefits From Philanthropic Pledge Which Triples Funds Raised
3/23/2011

Philanthropists Foster and Lynn Friess will triple-match the public's donations - up to a total of $100,000 - for TGen's 2nd annual unTEAL a cure ovarian cancer event. That means a donation of $100 will be matched by $300, generating a total of $400 for biomedical research at the Translational Genomics Research Institute (TGen)...